摘要
应用单克隆抗体ＳＺ－５１，通过放射免疫分析测定了９４例冠心病患者血小板α颗粒膜蛋白（ＧＭＰ－１４０）的活化分子数。实验结果表明：冠心病组患者血小板ＧＭＰ－１４０活化分子数比对照组明显增高（Ｐ＜０．００１），急性心肌梗塞（ＡＭＩ）患者用尿激酶溶栓治疗后１２ｈ的血小板ＧＭＰ－１４０活化分子数比治疗前１ｈ明显降低（Ｐ＜０．００１）。冠心病患者自身血小板数与血小板ＧＭＰ－１４０分子数无线性相关关系（ｒ＝０．０３９，Ｐ＞０．５０），因此我们认为冠心病患者血小板ＧＭＰ－１４０的检测，对冠心病诊断及鉴别诊断，尤其对ＡＭＩ的病因分析、治疗及预后判断都具有重要价值。
With monoclonal antibody SZ 51, the activated levels of the platelet granule membrane protein(GMP 140) of 94 cases with coronary heart disease (CHD) are assayed by RIA. The results show that the levels of GMP 140 with CHD are much higher than those of the controls ( P <0.001), and the levels of GMP 140 with AMI 12 hours after the treatment with urokinase for thrombolysis are considerably lower than the levels one hour before the treatment. Therefore, the assay of GMP 140 with CHD is of great clinical significance in diagnosing and differentiating CHD, especially, in analysing pathogeny, monitoring curative effect and predicting prognosis for AMI.
出处
《同位素》
CAS
北大核心
1996年第1期54-56,共3页
Journal of Isotopes
关键词
血小板
颗粒膜蛋白
冠心病
放射免疫分析
platelet granule membrane coronary heart disease radioimmunoassay(RIA)
